Novartis selects Qualcomm Life and its 2net technology

Qualcomm Incorporated's subsidiary, Qualcomm Life, Inc., has been selected by Novartis, a global pharmaceutical leader, as a global digital health collaborator for its Trials of The Future programme. Qualcomm Life’s 2net Platform will serve as a global connectivity platform for collecting and aggregating medical device data during clinical trials to improve the convenience and speed of capturing study participant data and test results to ultimately gain more trial efficiencies and connected experiences for participants.

The Trials of The Future programme is designed to leverage health care technology to improve the experience of clinical trial participants and patients using Novartis products, and provide connectivity with future products marketed by Novartis. Novartis will combine the 2net Platform, 2net Hub and 2net Mobile technologies with designated medical devices to automate the collection of vital patient data at patient’s homes during clinical trials.

“Novartis is a pioneer in putting technology to use in advancing pharmaceutical innovation,” said Rick Valencia, senior vice president and general manager, Qualcomm Life. “Standardising on the tech-agnostic 2net Platform and accessing the robust ecosystem of integrated medical devices will provide them a great range of flexibility and scalability, ultimately accelerating their efforts to design more efficient, cost-effective clinical trials.”